Please ensure Javascript is enabled for purposes of website accessibility

Why Ocugen Stock Fell 31.1% in May

By Jim Halley - Jun 7, 2021 at 6:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharmaceutical company, known for its portfolio of eye therapy drugs, has a COVID-19 vaccine in the works.

What happened

Shares of biopharmaceutical company Ocugen (OCGN 5.97%) dropped by 31.1% in May, according to S&P Global Market Intelligence data. Investors were concerned because the downward trend in COVID-19 cases in the United States could hurt the chances for the company's vaccine, which it is developing with India's Bharat Bioscience. With Ocugen's odds for bringing a profitable vaccine to market declining, investors may be taking a harder look at the company's financials, which showed a $7.1 million loss in the first quarter.

Frustrated man in front of a downward-looking stock chart.


So what

Ocugen's stock is up by more than 3,389% over the past 12 months and more than 376% this year. Those massive gains were predicated on the possibility that its candidate coronavirus vaccine COVAXIN, which the company says is effective against the new COVID-19 variants of concern, would be approved -- and be profitable.

On May 26, Ocugen said it is on track to submit an emergency use authorization (EUA) application for COVAXIN to the FDA in June. The problem is that the agency recently said it may refuse to grant new EUAs to vaccine makers that have not been working closely with the regulator during their candidates' development. The company has said that it believes it will meet the FDA's new EUA guidelines. In the meantime, however, the need for additional new vaccines in the United States is dropping, along with new COVID-19 case rates here. According to the Centers for Disease Control and Prevention, the seven-day average for daily new COVID-19 cases in the United State was 12,780 on June 4. The last time the number was that low was back in March 2020.

Now what

There's a lot of risk involved with this biotech stock. There's a good possibility that COVAXIN may not be granted an EUA, based on the FDA's recent statement. Even if it does get that EUA, Ocugen's vaccine is coming late to the party, putting it at a significant disadvantage to the entrenched COVID-19 vaccines, at least in the U.S. market.

There's plenty to still like about Ocugen, of course. The company has a pipeline of eye therapies through its modifier gene platform that it is developing to treat retinal degeneration. It also has a novel biologic under development as a therapy for diabetic retinopathy and diabetic macular edema, as well as for wet age-related macular degeneration. However, those treatments are all in the early stages of development. None have entered clinical trials yet. Without a blockbuster therapy, any purchase of Ocugen stock must be viewed as speculative. There's a good chance the share price could fall further.

The problem for any investor coming in now is that even after its recent price drop, this stock still carries a higher valuation than it warrants, trading at a high price-to-book ratio of 43.32.

Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
$2.84 (5.97%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.